Skip to content

Detection of Significant Coronary Artery Disease by Promising Biomarker: A2A Adenosine Receptor (A2AR) Assays

Detection of Significant Coronary Artery Disease by Promising Biomarker: A2A Adenosine Receptor (A2AR) Assays

Status
Active, not recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT05091749
Acronym
ADOCAD
Enrollment
312
Registered
2021-10-25
Start date
2021-11-09
Completion date
2025-12-01
Last updated
2025-06-03

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Chronic Coronary Syndromes

Brief summary

Transversal, national, multi-center study with progressive recruitment designed to assess the diagnostic accuracy of A2AR expression for the identification of significant obstructive CAD (FFR\<0.8) of patients suspected of CCS compared to the gold standard. 1. To assess the diagnostic accuracy of the A2AR profile (i.e. KD/EC50) for identifying myocardial ischemia in patients with suspected CCS compared to the gold standard inducible myocardial ischemia. 2. To determine the best threshold value for A2AR expression for identifying significant obstructive CAD (FFR\<0,8) in patients with CCS, and to estimate the diagnostic performances associated with the identified threshold 3. To determine the best threshold value for A2AR profile (i.e. KD/EC50) for identifying myocardial ischemia (See annex 2) in patients with CCS and to estimate the diagnostic performances associated with the identified threshold.

Interventions

BIOLOGICALblood samples

troponin measurement

Sponsors

Assistance Publique Hopitaux De Marseille
Lead SponsorOTHER

Study design

Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
DIAGNOSTIC
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Man or woman aged ≥18 and \<90 years old; * Must not be of child-bearing potential (≥1 year post-menopausal, contraceptive, or surgically sterile); * Symptoms suggestive of CCS and intermediate PTP (15-85%) according to the Diamond classification (2); * Undergone at least one stress imaging test (annex 3) or an abnormal coronary Computed Tomography Angiography (CTA) with the recommendation to perform ICA with FFR in all intermediate lesions; * Non-contributive ECG (resting 18-lead); * Normal echocardiography with left ventricular ejection fraction (LVEF) \>50%; * Cardiac troponin level \<99th percentile; * Intended for an invasive strategy for CCS; * Affiliated to or beneficiary of, a social security system; * Signed written informed consent.

Exclusion criteria

Persons referred in articles L.1121-5 to L.1121-8 and L.1122-2 of the Public Health Code: * Pregnant, parturient or breastfeeding woman * Person deprived of liberty for judicial or administrative decision * Person under psychiatric care * Minor person (non-emancipated) * History of CAD or known CAD * Suspected acute coronary syndrome (ACS: annex 4) * Inability to undergo adenosine testing * Allergy to iodinated contrast media * Bleeding diathesis * Known significant bleeding risk according to physician judgment * Severe hepatic failure (ASAT, ALAT\>3ULN) * Ischemic stroke within 1 month or a history of hemorrhagic stroke * Bradycardia * Platelet count \<100 G/L * Hemoglobin \<10g/dl * Major surgery or trauma within 10 days * Life expectancy \<1 year * Pre-test Probability \<15% or \>85% * History and clinical examination suggesting non-cardiac chest pain * Contraindication to coronary angiography * Thyroid disorder * Refusal to participate

Design outcomes

Primary

MeasureTime frameDescription
A 2AR measure24 MONTHSblood sample

Countries

France

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026